The right GLP-1 maintenance dose is the lowest dose that holds your weight and your metabolic markers, and for many people that sits below the top of the titration ladder. If your dose keeps climbing and your monthly bill keeps climbing with it, the problem is rarely your biology alone; it is often a business model that earns more at every step up. This guide explains what a maintenance dose actually is, what the trial data says about dose and durability, which biomarkers decide when to hold or taper, and how to tell whether the platform you are on profits from your dose going up.
- A GLP-1 maintenance dose is the lowest dose that sustains your goal weight and metabolic markers without intolerable side effects, and it is an individual number, not a protocol step.
- In STEP 1 and SURMOUNT 1, average weight loss rose with dose, but the largest share of benefit arrives before the top dose while side effects do not.
- HbA1c, fasting insulin, ApoB, hs-CRP, body composition and symptom burden decide when to hold, taper or increase; the scale alone decides nothing.
- Dose-escalation platforms commonly reprice as the dose climbs; a flat clinical fee is the same at every dose and every molecule.
- If your labs improve and your symptoms resolve, the correct next dose can be lower, or none.
What the trial data actually says about dose
The headline trial numbers are real and worth knowing precisely. In STEP 1, adults with overweight or obesity taking 2.4 mg of weekly semaglutide lost an average of roughly 15 percent of body weight over 68 weeks, against about 2 percent for placebo. In SURMOUNT 1, the highest dose of weekly tirzepatide produced average losses of up to about 22.5 percent at 72 weeks. Those are averages across thousands of participants, and individual results vary widely.
What the averages hide is the shape of the dose response. Most of the weight loss arrives early and at lower doses, and each further titration step buys a smaller increment for more people while increasing the gastrointestinal side effects that make people quit. STEP 4 showed that continuing semaglutide maintains a loss that stopping forfeits, which argues for staying on treatment, not for climbing forever. The clinically honest reading of the trials is this: the goal is the smallest dose that keeps the result you have, because more dose beyond that point is where the side effect burden, the cost and the risk live.
What a maintenance dose actually is
A maintenance dose is not a number printed in a protocol. It is the dose at which three things are simultaneously true: your weight holds at or near your goal, your metabolic markers are moving in the right direction or already sit where your clinician wants them, and the side effects are tolerable enough that you would take the medication for years without resentment. If any leg of that stool fails, the dose is wrong in one direction or the other.
This is also why the question of a universal maintenance dose has no answer. Some people hold their result on the lowest starting dose. Others need mid-range dosing. A few genuinely need the top dose, and when they do, it should be because their biology asked for it, not because a pricing tier did. The clinical guidance we work from has no profit motive in either direction: titrate to the least medicine that gets you the most result.
If a weight loss platform cannot answer the question of when your dose would come down with anything more specific than a shrug, ask what happens to their revenue when it does.
The biomarkers that decide when to hold or taper
In our model, dose decisions follow the quarterly Biomarker Audit, not the scale and not the calendar. One comprehensive panel every 90 days carries HbA1c and insulin markers, the lipid and inflammation work (ApoB, Lp(a), hs-CRP), and full hormone and thyroid panels, because weight, blood sugar, lipids and hormones are one system and the dose that serves one lane can strain another.
Dose decisions follow the labs
What each marker changes
| Marker or measure | What it tells your clinician | Typical dose consequence |
|---|---|---|
| HbA1c and fasting insulin | Whether glucose control is still improving | Improving labs at goal weight argue to hold or taper |
| ApoB and hs-CRP | Whether cardiovascular risk is actually falling | Sustained improvement supports the lowest effective dose |
| Body composition and strength | How much of the loss is muscle rather than fat | Rising muscle loss argues for slowing or reducing the dose |
| Symptom burden | Nausea, reflux, fatigue, food aversion | Intolerable symptoms argue for a lower dose regardless of the scale |
The body composition row is the one most programs skip, and it matters more as doses climb. Rapid loss without resistance training and adequate protein strips lean mass along with fat, which worsens the very metabolic markers the medication was prescribed to improve. Our protocol pairs every titration decision with muscle preservation guidance for exactly that reason.
Why dose escalation keeps happening to people
Here is why this question is worth an entire article. The dominant telehealth weight loss model advertises a low membership and earns its real margin inside the medication: an upcharge on the molecule, and often a repricing schedule that rises as your dose titrates. At maintenance doses on higher tiers, patients on those platforms commonly report paying $600 to $899 per month, figures we cite with hedges because they are reported across platforms rather than printed on one pricing page. The structure rewards escalation whether or not escalation is clinical.
There is a second structural detail. Zepbound and Mounjaro are the same molecule, tirzepatide, priced very differently. A cash-pay patient should be routed to Zepbound; Mounjaro belongs to insurance-covered type 2 diabetes care. A platform that earns a spread on the molecule has no reason to make that routing obvious. We earn nothing from the prescription either way, because every medication is billed by the pharmacy at pharmacy cost with zero markup, no molecule upcharge and no dose-escalation fee. One flat fee for the doctor. Zero markup on the medicine.
How titration actually works here
Membership begins with a clinical intake and your first comprehensive Biomarker Audit, and the written protocol that follows names the starting dose, the titration schedule and the stopping rules. Monthly check-ins adjust for symptoms and adherence between audits. Every 90 days the full panel is repeated and read against the last one, because a trend carries more information than a snapshot, and the dose conversation happens against that trend.
Clinical care is delivered by licensed physicians of Beluga Health, P.A., an independent Florida professional corporation licensed to practice in all 50 states, working under GoodLife Health's clinical protocols. All labs run through the Beluga Health lab network, and labs beyond the quarterly cadence are billed at pass-through cost. Only branded, FDA-approved medications are prescribed: Wegovy, Zepbound, Ozempic, Mounjaro, Wegovy Tablets and Foundayo (orforglipron). Never compounded GLP-1, under any circumstance.
The structural detail that makes honest titration possible is the one we keep returning to: when nobody in the chain earns a dollar from the prescription, deprescribing becomes a normal clinical act. If your labs improve and your weight holds on less medicine, lowering the dose is the obvious next step rather than a threat to anyone's revenue.
What it costs, and why the fee cannot move with your dose
The numbers, stated plainly. Membership is one flat $299 per month for the clinical layer: the quarterly Biomarker Audit, the clinician who reads it and answers between visits, the written protocol and the titration management. The first charge at checkout is $598, which covers the first two months together: the intake visit, the first comprehensive panel, and the second month of clinical care while your protocol is established. From month three it is $299 per month, month to month, and you can cancel anytime after the initial commitment.
The medicine is a separate charge, billed by the pharmacy at pharmacy cost. We never see a cent of it. Whether your protocol calls for branded semaglutide, branded tirzepatide, an oral option, or no medication at all, the $299 does not change. We make money when you get healthier, not when your dose gets stronger. If you have been burned by dose-based repricing before, the comparison page on the true monthly cost of GLP-1 telehealth lays out the math side by side.
The objection we hear most
A fair one: why should I pay $598 before I have lost anything? Because the first two months are where the diagnosis happens, and diagnosis is the part that cheap programs skip. A low advertised membership with a margin hiding in the medication needs you on the highest dose as fast as possible, which is why so many people arrive on our doorstep mid-titration with no labs ever drawn. The $598 buys the panel, the reading of the panel, the protocol and the second month of care, and it is the reason the fee never has to climb later. If that structure sounds like the one you have been looking for, start with the eligibility assessment.
FAQ
What is a GLP-1 maintenance dose? It is the lowest dose of a GLP-1 medication that sustains your goal weight and your metabolic markers without intolerable side effects. It is determined individually from labs, weight trend and symptoms, and it can sit below the top dose tested in the trials.
Is a higher dose always better for weight loss? No. Average weight loss in the trials rises with dose, but the largest share of benefit arrives before the top dose, side effects increase with dose, and individual response varies widely. The clinically useful dose is the smallest one that holds the result.
How is the maintenance dose chosen? Against the quarterly Biomarker Audit, which carries HbA1c, insulin markers, ApoB, Lp(a), hs-CRP and full hormone and thyroid panels, together with weight trend, body composition and symptom burden. The scale alone never decides.
Can you come down off a GLP-1 after reaching goal weight? Yes. A planned taper with continued monitoring is a legitimate clinical strategy. Trial data shows weight regain is common when treatment stops without a plan, which is why a taper is supervised and retested at the 90-day audits rather than improvised.
Does the GoodLife Health fee change with the dose? No. The membership is a flat $299 per month at every dose and every molecule, after a $598 first charge covering the first two months. Medication is billed separately by the pharmacy at pharmacy cost with zero markup.
Why do some platforms raise the price as the dose goes up? Because their margin lives inside the medication. A low advertised membership with dose-based repricing earns more as you titrate, commonly reaching $600 to $899 per month at maintenance tiers, figures commonly reported rather than printed on one page. The structure rewards escalation whether or not it is clinically indicated.
How often should a GLP-1 dose be reviewed? At monthly check-ins for symptoms and adherence, and formally against a full Biomarker Audit every 90 days, four times per year. A dose that has never been re-tested against a panel is a guess, not a protocol.
Related guides
- Cardiometabolic optimization: the definitive guide
- The GLP-1 dose-escalation trap
- Compounded GLP-1 vs brand-name: why we only prescribe branded
- Medical weight loss at GoodLife Health
- Biomarker audits vs standard blood tests
References
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1, New England Journal of Medicine). 2021. pubmed.ncbi.nlm.nih.gov/33567185/
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1, New England Journal of Medicine). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
- Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4, New England Journal of Medicine). 2021. pubmed.ncbi.nlm.nih.gov/33470712/